Jacc: Cardiooncology最新文献

{"title":"Redefining Gamification for Cardiovascular Prevention in High-Risk Cancer Survivors","authors":"Yuanyuan Yang MD","doi":"10.1016/j.jaccao.2025.11.005","DOIUrl":"10.1016/j.jaccao.2025.11.005","url":null,"abstract":"","PeriodicalId":48499,"journal":{"name":"Jacc: Cardiooncology","volume":"8 2","pages":"Page 205"},"PeriodicalIF":12.8,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147727013","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cardiovascular Adverse Events Associated With Bispecific T-Cell Engager Therapy","authors":"Osnat Itzhaki Ben Zadok MD, MSc ,&nbsp;Shai Shimony MD, MPH ,&nbsp;Shannon Miller CNP ,&nbsp;David Stein PhD ,&nbsp;Shahrier Hossain PharmD ,&nbsp;Giada Bianchi MD ,&nbsp;Anju Nohria MD, MSc","doi":"10.1016/j.jaccao.2026.01.005","DOIUrl":"10.1016/j.jaccao.2026.01.005","url":null,"abstract":"<div><h3>Background</h3><div>Although some cancer immunotherapies have been linked to increased cardiovascular risk, data on T-cell engager (TCE) therapy–associated cardiovascular complications remain limited.</div></div><div><h3>Objectives</h3><div>This study sought to characterize the incidence and factors associated with cardiovascular events (CVEs) and mortality during TCE therapy.</div></div><div><h3>Methods</h3><div>We conducted a dual-center retrospective study of patients with cancer treated with TCEs between 2016 and 2024. The cumulative incidence of on-treatment CVEs (heart failure, arrhythmias, myocardial infarction, stroke) and cardiovascular mortality was evaluated using Fine-Gray competing-risks models incorporating time-dependent grade ≥2 cytokine-release syndrome (CRS) and/or immune effector cell–associated neurotoxicity syndrome (ICANS). Factors associated with all-cause mortality were assessed using Cox models including CVEs as a time-dependent covariate.</div></div><div><h3>Results</h3><div>Among 567 patients (median age 67 years [Q1-Q3: 57-75]; 46.0% female), 25.9% had preexisting cardiovascular disease. The most common malignancies were multiple myeloma (40.9%) and acute lymphoblastic leukemia (35.6%). The restricted mean follow-up was 248 days (range: 0-973), during which 65 CVEs occurred (cumulative incidence 10.4%; 95% CI: 8.1-13.1), most commonly new left ventricular dysfunction (2.3%) and new-onset atrial fibrillation (2.1%). Cardiovascular mortality was rare (2 cases, 0.4%). Coronary artery disease was the only baseline variable independently associated with CVEs, whereas development of grade ≥2 CRS and/or ICANS was associated with a significant time-dependent increase in CVE risk. CVEs were significantly associated with higher all-cause mortality, independent of baseline clinical factors and TCE agent.</div></div><div><h3>Conclusions</h3><div>TCE therapy demonstrates a favorable cardiovascular safety profile overall, yet cardiovascular complications during therapy are associated with markedly increased mortality risk. Patients with preexisting coronary artery disease and those who develop high-grade CRS and/or ICANS represent high-risk groups that may benefit from intensified cardiovascular assessment and monitoring.</div></div>","PeriodicalId":48499,"journal":{"name":"Jacc: Cardiooncology","volume":"8 2","pages":"Pages 152-164"},"PeriodicalIF":12.8,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147470007","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cardiac Biomarker Complete Response in Light Chain Amyloidosis","authors":"Alexander H. Gunn MD ,&nbsp;Cristiana Costa Chase DO ,&nbsp;Michel G. Khouri MD","doi":"10.1016/j.jaccao.2026.02.003","DOIUrl":"10.1016/j.jaccao.2026.02.003","url":null,"abstract":"","PeriodicalId":48499,"journal":{"name":"Jacc: Cardiooncology","volume":"8 2","pages":"Pages 148-151"},"PeriodicalIF":12.8,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147726982","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Elevated Plasma IL-18 Levels During Chemotherapy Treatment for Breast Cancer, Exercise Capacity, and Physical Activity","authors":"Moriah P. Bellissimo PhD, RD ,&nbsp;Matthew Ambrosio MS ,&nbsp;Adolfo Gabriele Mauro PhD ,&nbsp;Eleonora Mezzaroma PhD ,&nbsp;Elisa N.D. Palladino PhD ,&nbsp;Bonnie Ky MD, MSCE ,&nbsp;Glenn J. Lesser MD ,&nbsp;Ralph B. D’Agostino Jr. PhD ,&nbsp;Fadi N. Salloum PhD ,&nbsp;W. Gregory Hundley MD","doi":"10.1016/j.jaccao.2026.03.001","DOIUrl":"10.1016/j.jaccao.2026.03.001","url":null,"abstract":"","PeriodicalId":48499,"journal":{"name":"Jacc: Cardiooncology","volume":"8 2","pages":"Pages 192-194"},"PeriodicalIF":12.8,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147726934","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cardiovascular Adverse Events Following Bispecific T-Cell Redirecting Antibody Therapy","authors":"Eli Grunblatt MD, PhD ,&nbsp;Sawsan A. Alkhalili BS ,&nbsp;Zhiying Meng MS ,&nbsp;Abigail S. Baldridge DrPH ,&nbsp;Shira Dinner MD ,&nbsp;Leo I. Gordon MD ,&nbsp;Jayesh Mehta MD ,&nbsp;Anjali Rao MD ,&nbsp;Seema Singhal MD ,&nbsp;Reem Karmali MD ,&nbsp;Nausheen Akhter MD","doi":"10.1016/j.jaccao.2026.02.001","DOIUrl":"10.1016/j.jaccao.2026.02.001","url":null,"abstract":"","PeriodicalId":48499,"journal":{"name":"Jacc: Cardiooncology","volume":"8 2","pages":"Pages 185-188"},"PeriodicalIF":12.8,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147726968","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Refining the Role of ERK Signaling in Anthracycline-Induced Cardiotoxicity","authors":"Zheyu Wang MD,&nbsp;Defeng Zhao MD","doi":"10.1016/j.jaccao.2025.10.005","DOIUrl":"10.1016/j.jaccao.2025.10.005","url":null,"abstract":"","PeriodicalId":48499,"journal":{"name":"Jacc: Cardiooncology","volume":"8 2","pages":"Page 209"},"PeriodicalIF":12.8,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147727001","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Risk Prediction in Cardio-Oncology: Conceptual and Methodological Considerations","authors":"Jonathan Sen MBBS, PhD ,&nbsp;Eitan Amir MD, PhD ,&nbsp;Peter C. Austin PhD ,&nbsp;Thomas H. Marwick MBBS, PhD, MPH ,&nbsp;Chris McIntosh PhD ,&nbsp;Paaladinesh Thavendiranathan MD, SM ,&nbsp;Husam Abdel-Qadir MD, PhD","doi":"10.1016/j.jaccao.2026.01.006","DOIUrl":"10.1016/j.jaccao.2026.01.006","url":null,"abstract":"<div><div>Risk prediction models can guide prevention, monitoring, and treatment decisions in cardio-oncology, but their development requires careful attention to methodological challenges unique to cardiovascular disease arising in the context of cancer. In this state-of-the-art review, the authors use case scenarios to illustrate how prediction objectives, index dates, and time horizons must align with specific clinical decisions across the cancer trajectory. They summarize key considerations for data source selection, population definition, sample size, and variable selection and discuss challenges in incorporating treatment data, including immortal time bias and confounding by indication. The authors review regression-based, competing risk, dynamic, and machine learning approaches for model development, along with best practices for evaluating discrimination, calibration, and clinical utility. Finally, they outline principles for implementation, including workflow integration, transparency, and ongoing model updating. Together, these concepts provide a framework to support the development and adoption of rigorous, clinically meaningful risk prediction tools tailored to cardio-oncology.</div></div>","PeriodicalId":48499,"journal":{"name":"Jacc: Cardiooncology","volume":"8 2","pages":"Pages 101-119"},"PeriodicalIF":12.8,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147726979","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cardiac Biomarker Complete Response in AL Amyloidosis","authors":"Eli Muchtar MD ,&nbsp;Susan Geyer PhD ,&nbsp;Angela Dispenzieri MD ,&nbsp;Martha Grogan MD ,&nbsp;Taxiarchis V. Kourelis MD ,&nbsp;Francis K. Buadi MD ,&nbsp;Prashant Kapoor MD ,&nbsp;David Dingli MD, PhD ,&nbsp;Wilson Gonsalves MD ,&nbsp;Nelson Leung MD ,&nbsp;Giampaolo Merlini MD ,&nbsp;Julie Rosenthal MD ,&nbsp;Barry Boilson MD ,&nbsp;Melissa Lyle MD ,&nbsp;Janell Grazzini Frantz MS, APRN ,&nbsp;Suzanne R. Hayman MD ,&nbsp;Martha Q. Lacy MD ,&nbsp;Mustaqeem Siddiqui MD ,&nbsp;Joselle Cook MBBS ,&nbsp;Nadine Abdallah MD ,&nbsp;Morie A. Gertz MD","doi":"10.1016/j.jaccao.2026.01.004","DOIUrl":"10.1016/j.jaccao.2026.01.004","url":null,"abstract":"<div><h3>Background</h3><div>Cardiac biomarker complete response (CR) is a new concept in amyloid light chain (AL) cardiac amyloidosis (CA).</div></div><div><h3>Objectives</h3><div>The aim of this study was to characterize patients with AL CA who achieved cardiac biomarker CR, including clinical presentation, treatment, cardiac recovery, and survival.</div></div><div><h3>Methods</h3><div>This single-center retrospective cohort study included patients diagnosed with AL CA between 2004 and 2023 who met cardiac biomarker response eligibility (baseline N-terminal pro–B-type natriuretic peptide [NT-proBNP] &gt;650 pg/mL or B-type natriuretic peptide &gt;150 pg/mL). Among these, patients who achieved cardiac biomarker CR, defined as NT-proBNP ≤350 pg/mL or B-type natriuretic peptide ≤80 pg/mL sustained for at least 12 months, were identified. The median follow-up duration was 9.5 years.</div></div><div><h3>Results</h3><div>Sixty-three patients achieved cardiac biomarker CR (4.7% of evaluable cases [63 of 1,342]). This proportion increased in the second period compared with the first (6.4% [38 of 591] vs 3.3% [25 of 751]; <em>P</em> &lt; 0.001). The median age was 57 years (Q1-Q3: 49-66 years), and 63.5% were men. The median baseline difference between involved and uninvolved free light chains was 429 mg/L (Q1-Q3: 143-708 mg/L), the median pretreatment NT-proBNP concentration was 1,977 pg/mL, and 57.1% of patients were in cardiac stage II. Hematologic CR preceded cardiac biomarker CR in 76% of patients. The median time to cardiac biomarker CR was 20.6 months. At cardiac biomarker CR, the median NT-proBNP concentration was 265 pg/mL (86.9% reduction from baseline). Echocardiographic parameters improved by the time of cardiac biomarker CR but did not fully normalize in all patients. Cardiac progression occurred in 14% of patients, and 44.4% required subsequent clone-directed therapy. Eight patients died, 2 of non–AL CA–related causes. Survival was comparable with that of a matched general U.S. population (<em>P</em> = 0.35).</div></div><div><h3>Conclusions</h3><div>Cardiac biomarker CR represents the deepest level of cardiac biochemical recovery in AL amyloidosis and is associated with survival similar to the general population. Despite biochemical recovery, structural cardiac abnormalities may persist, underscoring the importance of early diagnosis and timely therapy.</div></div>","PeriodicalId":48499,"journal":{"name":"Jacc: Cardiooncology","volume":"8 2","pages":"Pages 137-147"},"PeriodicalIF":12.8,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147726981","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Myocardial Expression of PD-L1 as a Marker of Poor Prognosis in Immune Checkpoint Inhibitor–Associated Myocarditis","authors":"Takuro Imaoka MD ,&nbsp;Shingo Sakashita MD, PhD ,&nbsp;Satoshi Matsuoka MD, PhD ,&nbsp;Kimi Sato MD, PhD ,&nbsp;Yoichi Naito MD, PhD ,&nbsp;Genki Okumura PhD ,&nbsp;Shohei Koyama MD, PhD ,&nbsp;Koji Hozawa MD ,&nbsp;Yuka Nakamura BS ,&nbsp;Yuma Shibutani PhD ,&nbsp;Tomoko Ishizu MD, PhD ,&nbsp;Ikuo Sekine MD, PhD ,&nbsp;Kazuko Tajiri MD, PhD","doi":"10.1016/j.jaccao.2026.03.006","DOIUrl":"10.1016/j.jaccao.2026.03.006","url":null,"abstract":"<div><h3>Background</h3><div>Immune checkpoint inhibitors (ICIs) have improved cancer outcomes but are associated with severe immune-related adverse events, including myocarditis. PD-L1 plays an important role in immune regulation and homeostasis. Myocardial PD-L1 up-regulation has been reported in ICI-associated myocarditis; however, its clinical significance and prognostic value remain unclear.</div></div><div><h3>Objectives</h3><div>This study sought to investigate the association between myocardial PD-L1 expression and ICI-associated myocarditis severity and prognosis.</div></div><div><h3>Methods</h3><div>Twenty consecutive cases of biopsy-proven ICI-associated myocarditis were analyzed. Endomyocardial biopsy specimens underwent immunohistochemical staining for PD-L1, and patients were categorized into high (≥8%) or low (&lt;8%) PD-L1 expression groups. Clinical presentation and the incidence of major adverse cardiotoxic events, defined as a composite of severe heart failure, severe arrhythmia, or cardiac death, were compared between groups.</div></div><div><h3>Results</h3><div>The median follow-up time for the cohort was 189 days (Q1-Q3: 88-308 days). The absolute risk of 30-day major adverse cardiotoxic events was significantly higher in the high PD-L1 group (n = 5 of 7 [71.4%], 95% CI: 29.0%-96.3%) than in the low PD-L1 group (n = 1 of 13 [7.7%], 95% CI: 0.2%-36.0%; <em>P</em> = 0.007). The median peak normalized troponin level (× upper limit of normal) was significantly higher in the high PD-L1 group than in the low PD-L1 group (662 [Q1–Q3: 204–855] vs 64 [Q1–Q3: 26–108]; <em>P</em> = 0.010). Patients in the high PD-L1 group also had longer QRS duration on electrocardiography (124 ms [Q1-Q3: 108-131 ms] vs 96 ms [Q1-Q3: 90-102 ms]; <em>P =</em> 0.021). Myocardial inflammatory cell infiltration was greater in the high PD-L1 group, with higher CD3⁺ T cell infiltration (35.9% [Q1-Q3: 25.8%-42.8%] vs 2.6% [Q1-Q3: 0.6%-5.8%]; <em>P =</em> 0.007) and higher CD68⁺ macrophage infiltration (15.2% [Q1-Q3: 10.2%-21.1%] vs 1.23% [Q1-Q3: 0.4%-2.3%]; <em>P =</em> 0.007).</div></div><div><h3>Conclusions</h3><div>High myocardial PD-L1 expression is associated with greater disease severity and a higher risk of major adverse cardiotoxic events in ICI-associated myocarditis. Assessment of PD-L1 expression in endomyocardial biopsy specimens may help identify patients at high risk who may benefit from early intervention and closer monitoring.</div></div>","PeriodicalId":48499,"journal":{"name":"Jacc: Cardiooncology","volume":"8 2","pages":"Pages 168-180"},"PeriodicalIF":12.8,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147727012","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Sotatercept for the Treatment of Myeloproliferative Neoplasm–Associated Group 5 Pulmonary Hypertension","authors":"Hyeon-Ju R. Ali MD ,&nbsp;Saadia A. Faiz MD ,&nbsp;Anita Deswal MD, MPH ,&nbsp;Nicolas Palaskas MD, MPH ,&nbsp;Cezar Iliescu MD ,&nbsp;Kara Thompson MD ,&nbsp;Maro Ohanian DO ,&nbsp;Naveen Pemmaraju MD ,&nbsp;Prithviraj Bose MD ,&nbsp;Sandeep Sahay MD, MSc","doi":"10.1016/j.jaccao.2026.02.002","DOIUrl":"10.1016/j.jaccao.2026.02.002","url":null,"abstract":"","PeriodicalId":48499,"journal":{"name":"Jacc: Cardiooncology","volume":"8 2","pages":"Pages 200-204"},"PeriodicalIF":12.8,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147575940","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}